Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

64 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial.
Delany-Moretlwe S, Hughes JP, Bock P, Ouma SG, Hunidzarira P, Kalonji D, Kayange N, Makhema J, Mandima P, Mathew C, Spooner E, Mpendo J, Mukwekwerere P, Mgodi N, Ntege PN, Nair G, Nakabiito C, Nuwagaba-Biribonwoha H, Panchia R, Singh N, Siziba B, Farrior J, Rose S, Anderson PL, Eshleman SH, Marzinke MA, Hendrix CW, Beigel-Orme S, Hosek S, Tolley E, Sista N, Adeyeye A, Rooney JF, Rinehart A, Spreen WR, Smith K, Hanscom B, Cohen MS, Hosseinipour MC; HPTN 084 study group. Delany-Moretlwe S, et al. Among authors: rinehart a. Lancet. 2022 May 7;399(10337):1779-1789. doi: 10.1016/S0140-6736(22)00538-4. Epub 2022 Apr 1. Lancet. 2022. PMID: 35378077 Free PMC article. Clinical Trial.
Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069/ACTG A5305).
Gulick RM, Wilkin TJ, Chen YQ, Landovitz RJ, Amico KR, Young AM, Richardson P, Marzinke MA, Hendrix CW, Eshleman SH, McGowan I, Cottle LM, Andrade A, Marcus C, Klingman KL, Chege W, Rinehart AR, Rooney JF, Andrew P, Salata RA, Magnus M, Farley JE, Liu A, Frank I, Ho K, Santana J, Stekler JD, McCauley M, Mayer KH. Gulick RM, et al. Among authors: rinehart ar. J Infect Dis. 2017 Jan 15;215(2):238-246. doi: 10.1093/infdis/jiw525. J Infect Dis. 2017. PMID: 27811319 Free PMC article. Clinical Trial.
Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial.
Markowitz M, Frank I, Grant RM, Mayer KH, Elion R, Goldstein D, Fisher C, Sobieszczyk ME, Gallant JE, Van Tieu H, Weinberg W, Margolis DA, Hudson KJ, Stancil BS, Ford SL, Patel P, Gould E, Rinehart AR, Smith KY, Spreen WR. Markowitz M, et al. Among authors: rinehart ar. Lancet HIV. 2017 Aug;4(8):e331-e340. doi: 10.1016/S2352-3018(17)30068-1. Epub 2017 May 22. Lancet HIV. 2017. PMID: 28546090 Clinical Trial.
Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women: A Phase 2 Randomized Trial.
Gulick RM, Wilkin TJ, Chen YQ, Landovitz RJ, Amico KR, Young AM, Richardson P, Marzinke MA, Hendrix CW, Eshleman SH, McGowan I, Cottle LM, Andrade A, Marcus C, Klingman KL, Chege W, Rinehart AR, Rooney JF, Andrew P, Salata RA, Siegel M, Manabe YC, Frank I, Ho K, Santana J, Stekler JD, Swaminathan S, McCauley M, Hodder S, Mayer KH. Gulick RM, et al. Among authors: rinehart ar. Ann Intern Med. 2017 Sep 19;167(6):384-393. doi: 10.7326/M17-0520. Epub 2017 Aug 22. Ann Intern Med. 2017. PMID: 28828489 Free PMC article. Clinical Trial.
Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial.
Landovitz RJ, Li S, Grinsztejn B, Dawood H, Liu AY, Magnus M, Hosseinipour MC, Panchia R, Cottle L, Chau G, Richardson P, Marzinke MA, Hendrix CW, Eshleman SH, Zhang Y, Tolley E, Sugarman J, Kofron R, Adeyeye A, Burns D, Rinehart AR, Margolis D, Spreen WR, Cohen MS, McCauley M, Eron JJ. Landovitz RJ, et al. Among authors: rinehart ar. PLoS Med. 2018 Nov 8;15(11):e1002690. doi: 10.1371/journal.pmed.1002690. eCollection 2018 Nov. PLoS Med. 2018. PMID: 30408115 Free PMC article. Clinical Trial.
Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial.
Murray MI, Markowitz M, Frank I, Grant RM, Mayer KH, Hudson KJ, Stancil BS, Ford SL, Patel P, Rinehart AR, Spreen WR, Margolis DA. Murray MI, et al. Among authors: rinehart ar. HIV Clin Trials. 2018 Aug;19(4):129-138. doi: 10.1080/15284336.2018.1511346. Epub 2018 Nov 16. HIV Clin Trials. 2018. PMID: 30445896 Clinical Trial.
Cabotegravir Is Not Associated With Weight Gain in Human Immunodeficiency Virus-uninfected Individuals in HPTN 077.
Landovitz RJ, Zangeneh SZ, Chau G, Grinsztejn B, Eron JJ, Dawood H, Magnus M, Liu AY, Panchia R, Hosseinipour MC, Kofron R, Margolis DA, Rinehart A, Adeyeye A, Burns D, McCauley M, Cohen MS, Currier JS. Landovitz RJ, et al. Among authors: rinehart a. Clin Infect Dis. 2020 Jan 2;70(2):319-322. doi: 10.1093/cid/ciz439. Clin Infect Dis. 2020. PMID: 31125395 Free PMC article. Clinical Trial.
Acceptability of Long-Acting Injectable Cabotegravir (CAB LA) in HIV-Uninfected Individuals: HPTN 077.
Tolley EE, Zangeneh SZ, Chau G, Eron J, Grinsztejn B, Humphries H, Liu A, Siegel M, Bertha M, Panchia R, Li S, Cottle L, Rinehart A, Margolis D, Jennings A, McCauley M, Landovitz RJ. Tolley EE, et al. Among authors: rinehart a. AIDS Behav. 2020 Sep;24(9):2520-2531. doi: 10.1007/s10461-020-02808-2. AIDS Behav. 2020. PMID: 32052214 Free PMC article. Clinical Trial.
Brief Report: Hormonal Contraception Use and Cabotegravir Pharmacokinetics in HIV-Uninfected Women Enrolled in HPTN 077.
Blair CS, Li S, Chau G, Cottle L, Richardson P, Marzinke MA, Eshleman SH, Adeyeye A, Rinehart AR, Margolis D, McCauley M, Hendrix CW, Landovitz RJ; HPTN 077 Study Team. Blair CS, et al. Among authors: rinehart ar. J Acquir Immune Defic Syndr. 2020 Sep 1;85(1):93-97. doi: 10.1097/QAI.0000000000002409. J Acquir Immune Defic Syndr. 2020. PMID: 32452972 Free PMC article.
64 results